The HinduLean L·
U.S. FDA approves AbbVie's drug for Parkinson's disease
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill
Read at The Hindu →
Science · 2 sources covering this
U.S. FDA approves AbbVie's drug for Parkinson's disease
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill
Coverage spectrum
2 L · 0 C · 0 R
How 2 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://hindustansphere.com/embed/cluster/ca0aef549c220eacfd9a1144ff056407d049c662" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="U.S. FDA approves AbbVie's drug for Parkinson's disease"></iframe>
